

# PRESS RELEASE



**HANSA**  
BIOPHARMA

## New imlifidase data presented at ESOT, Copenhagen

Lena Winstedt, PhD, Head of Science at Hansa Biopharma, will present results from a pooled analysis of Phase 2 trials with imlifidase for desensitization in sensitized kidney transplant patients.

**Lund, Sweden August 30, 2019.** Hansa Biopharma, the leader in immunomodulatory enzyme technology for rare IgG-mediated diseases, announced today that new imlifidase data will be highlighted in a presentation at the 19th Congress of the European Society for Organ Transplantation (ESOT), taking place September 15 to 18, 2019 in Copenhagen, Denmark.

In an oral poster session on Tuesday, September 17, 2019 at 8-9am CET, Lena Winstedt, PhD, Head of Science at Hansa Biopharma, will present "Imlifidase For Desensitization in Sensitized Kidney Transplant Patients: Pooled Analysis of Phase 2 Trials".

The presentation will report a pooled analysis of transplanted patients from four single arm, 6-month, open label, Phase 2 trials of imlifidase treatment prior to deceased and living donor transplantation in sensitized patients. This is the first time these data on the pooled 46-patient cohort will be presented.

The results show that imlifidase treatment rapidly and prior to transplantation inactivated donor specific antibodies (DSAs) and converted positive crossmatches to negative. The overall patient and graft outcome was good and the AMR incidence was consistent with expectations and successfully managed. Details on the presentation are as follows:

**Title:** Imlifidase For Desensitization in Sensitized Kidney Transplant Patients: Pooled Analysis of Phase 2 Trials

**Time and Date:** Tuesday, September 17, 2019 at 8-9am (CET)

**Session:** OS25 – Kidney immunosuppression - new advances

**Abstract Number:** 4381953

**Location:** Auditorium 15

The information was submitted for publication, through the agency of the contact person set out below at 08:00 (CET) on August 30, 2019.

### Contact information

Klaus Sindahl  
Head of Investor Relations  
Hansa Biopharma  
M: +46 (0) 709-298 269  
E: klaus.sindahl@hansabiopharma.com

Rolf Gulliksen  
Head of Corporate Communications  
Hansa Biopharma  
M: +46 (0) 733-328 634  
E: rolf.gulliksen@hansabiopharma.com

### About Hansa Biopharma

Hansa Biopharma is harnessing its proprietary immunomodulatory enzyme technology platform to develop treatments for rare immunoglobulin G (IgG)-mediated autoimmune conditions, transplant rejection and cancer.

The Company's lead product, imlifidase, is a unique antibody-degrading enzyme to enable kidney transplantation in highly sensitized patients with potential for further development in other solid organ transplantation and acute autoimmune indications. Imlifidase is currently under potential marketing authorization by EMA. Hansa's research and development program is advancing the next generation of the Company's technology to develop novel IgG-cleaving enzymes with lower immunogenicity, suitable for repeat dosing in relapsing autoimmune diseases and oncology.

Hansa Biopharma is based in Lund, Sweden and also has operations in the UK and US.

Hansa Biopharma  
Scheelevägen 22  
SE- 223 63 Lund, Sweden  
Phone: +46 46 16 56 70  
[www.hansabiopharma.com](http://www.hansabiopharma.com)

Nasdaq OMX Stockholm  
Ticker: HNSA  
ISIN: SE 0002148817